Norelgestromin/ethinylestradiol
Norelgestromin/ethinylestradiol, sold under the brand name Ortho Evra among others, is a contraceptive patch containing the progestin norelgestromin and the estrogen ethinylestradiol. As of December 2016, the product Ortho Evra has been discontinued in the U.S. while the product Xulane continues to be marketed.

The most common side effects include headache, nausea (feeling sick), breast tenderness, and irregular uterine bleeding.

Norelgestromin/ethinylestradiol was approved for medical use in the United States in November 2001, and in the European Union in August 2002.

Norelgestromin/ethinylestradiol is a transdermal patch (a patch that delivers a medicine across the skin). For the first three weeks of the menstrual cycle a new patch should be applied every week, followed by a fourth week, which is patch-free. The patch-free interval must not be longer than seven days; otherwise, additional non-hormonal contraceptive methods must be used, such as condoms. Transdermal patches must always be applied on the same day of the week to the buttock, abdomen (belly), upper arm or upper back. The same area of skin should not be used for two consecutive patches. Norelgestromin/ethinylestradiol may work less well in women weighing or more.
Q1295013
contraceptive patch
Concept
Q50383885
progestin
Concept
Q15295638
norelgestromin
Concept
Q277954
estrogen
Concept
Q415563
ethinylestradiol
Concept
Q28209704
Norelgestromin/ethinylestradiol
MEDIA
Q28209704
Norelgestromin/ethinylestradiol
MEDIA
Q28209704
Norelgestromin/ethinylestradiol
MEDIA
Q28209704
Norelgestromin/ethinylestradiol
MEDIA
2016-12-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
December 2016
DATE
2001-11-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
November 2001
DATE
2002-08-01T00:00:00Z^^http://www.w3.org/2001/XMLSchema#dateTime
August 2002
DATE
part of
part of
subject has role